Outpace Bio utilizes AI-powered protein design to engineer novel biological functions for cell therapies. The company develops platform technologies like OUTSPACER™, OUTSMART™, and OUTLAST™ to enhance the potency, persistence, and safety of these treatments against solid tumors. This approach programs engineered cells to make optimal decisions within the tumor microenvironment to achieve durable clinical responses.
Funding
$199M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing cell therapies face challenges in effectively targeting and eliminating solid tumors due to immune suppression within the tumor microenvironment, limited persistence of therapeutic cells, and difficulties in distinguishing cancer cells from healthy tissue. These limitations hinder the broad applicability and curative potential of cell-based cancer treatments.
Solution
Outpace Bio leverages AI-driven protein design to engineer cell therapies with enhanced functionality and specificity for solid tumors. Their approach focuses on overcoming immune suppression by stimulating productive immune responses within the tumor microenvironment, improving cell therapy persistence through optimized cell programming, and maximizing the potency and safety of cell therapies by precisely targeting cancer cells. By designing novel protein functions, Outpace Bio aims to guide cells to make the right decisions inside patients, leading to more effective and durable clinical responses. The company's platform technologies are designed to be compatible with various cell types and manufacturing approaches, enabling the development of best-in-class cell therapy products.
Target Audience
Outpace Bio's primary target audience includes biopharmaceutical companies and academic institutions involved in developing and commercializing cell therapies for solid tumors.
Features
- OUTSMART™: Designed cytokines to stimulate immune cells within the tumor microenvironment, boosting efficacy and safety.
- OUTLAST™: Technology to reprogram cell therapies for enhanced persistence and durable clinical responses.
- OUTSPACER™: Optimized CAR constructs to maximize CAR T cell function and potency.
- OUTSAFE™ (EGFRopt™): A fully human safety switch that responds to cetuximab, enabling controlled cell therapy activity and use for cell selection/QC.
- CO-LOCKR™: Logic-gated targeting technology to recognize unique protein fingerprints on cancer cells, improving specificity and safety.
- AI-powered protein design platform for creating novel protein functions and programming cells.
- Integrated computational and structural biology, synthetic biology, cell programming, and translational immunology capabilities.